{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,24]],"date-time":"2026-07-24T09:39:12Z","timestamp":1784885952805,"version":"3.55.0"},"reference-count":29,"publisher":"Oxford University Press (OUP)","issue":"1","license":[{"start":{"date-parts":[[2025,12,16]],"date-time":"2025-12-16T00:00:00Z","timestamp":1765843200000},"content-version":"vor","delay-in-days":1,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"name":"Assertio Holdings, Inc"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,12,27]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Febrile neutropenia (FN) is a common complication with myelosuppressive chemotherapy regimens, significantly affecting patients with breast cancer (BC) receiving docetaxel and cyclophosphamide (TC). Treatment with granulocyte colony-stimulating factor (G-CSF) is established for prophylactic and therapeutic use to reduce risk of FN. Eflapegrastim-xnst, a novel long-acting G-CSF, has a favorable safety profile and is effective in reducing neutropenia risk in patients with early-stage BC receiving TC, when administered 24\u2009h after chemotherapy. The benefits of eflapegrastim-xnst given same day as TC have not been evaluated in a randomized controlled trial.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Patients and Methods<\/jats:title>\n                    <jats:p>This phase 1, multicenter, open-label trial evaluated efficacy and safety of eflapegrastim-xnst administered 0.5\u2009h post-TC chemotherapy for four cycles in patients with early-stage BC. The primary end point was time to recovery of absolute neutrophil count (ANC) from nadir to \u22651.5\u2009\u00d7\u2009109\/L in cycle 1. Secondary end points included safety, duration of severe neutropenia, incidence of FN, and neutropenic complications.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Of 53 patients enrolled, 49 completed the study. Mean time to ANC recovery in cycle 1, the primary end point, was 1.8\u2009days. Only 1 patient (2%) experienced an FN episode in cycle 1 (1 episode\/228 cycles received [0.4%]). Incidence of severe neutropenia decreased from 42.9% (cycle 1) to 27.3% (cycle 4). Eflapegrastim-xnst was well tolerated; common treatment-emergent adverse events included fatigue, nausea, alopecia, and bone pain.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Eflapegrastim-xnst, administered same day as TC chemotherapy was effective and well tolerated evidenced by short time to neutrophil recovery and low incidence of FN, with an adverse event profile similar to that of next-day dosing.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/oncolo\/oyaf415","type":"journal-article","created":{"date-parts":[[2025,12,13]],"date-time":"2025-12-13T13:00:11Z","timestamp":1765630811000},"source":"Crossref","is-referenced-by-count":1,"title":["Safety and efficacy of same-day administration of eflapegrastim in patients with early-stage breast cancer receiving chemotherapy"],"prefix":"10.1093","volume":"31","author":[{"given":"Manuel","family":"Modiano","sequence":"first","affiliation":[{"name":"Arizona Clinical Research Center , Tucson, AZ 85715,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shanta","family":"Chawla","sequence":"additional","affiliation":[{"name":"Spectrum Pharmaceuticals, Inc ., Irvine, CA 92618,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey L","family":"Vacirca","sequence":"additional","affiliation":[{"name":"New York Cancer Specialists , East Setauket, NY 11733,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenneth","family":"Crist","sequence":"additional","affiliation":[{"name":"Assertio Holdings, Inc ., Lake Forest, IL 60045,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Howard","family":"Franklin","sequence":"additional","affiliation":[{"name":"Assertio Holdings, Inc ., Lake Forest, IL 60045,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7433-3428","authenticated-orcid":false,"given":"Lee","family":"Schwartzberg","sequence":"additional","affiliation":[{"name":"Renown Health-Pennington Cancer Institute , Reno, NV 89502,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2025,12,15]]},"reference":[{"key":"2026010713412918600_oyaf415-B1","first-page":"39","article-title":"Rolvedon from Spectrum Pharmaceuticals, Inc","volume":"89","author":"Holmberg","year":"2023","journal-title":"Pharm Times"},{"key":"2026010713412918600_oyaf415-B2","doi-asserted-by":"crossref","first-page":"102427","DOI":"10.1016\/j.ctrv.2022.102427","article-title":"Chemotherapy-induced neutropenia and emerging agents for prevention and treatment: a review","volume":"109","author":"Blayney","year":"2022","journal-title":"Cancer Treat Rev"},{"key":"2026010713412918600_oyaf415-B3","volume-title":"Rolvedon\u00ae (Eflapegrastim-Xnst) Prescribing Information","year":"2022"},{"key":"2026010713412918600_oyaf415-B4","doi-asserted-by":"crossref","first-page":"6234","DOI":"10.1002\/cam4.3227","article-title":"A comparison of eflapegrastim to pegfilgrastim in the management of chemotherapy-induced neutropenia in patients with early-stage breast cancer undergoing cytotoxic chemotherapy (RECOVER): a phase 3 study","volume":"9","author":"Cobb","year":"2020","journal-title":"Cancer Med"},{"key":"2026010713412918600_oyaf415-B5","doi-asserted-by":"crossref","first-page":"e1233","DOI":"10.1634\/theoncologist.2020-0105","article-title":"Eflapegrastim, a long-acting granulocyte-colony stimulating factor for the management of chemotherapy-induced neutropenia: results of a phase III trial","volume":"25","author":"Schwartzberg","year":"2020","journal-title":"Oncologist"},{"key":"2026010713412918600_oyaf415-B6","doi-asserted-by":"crossref","first-page":"5555","DOI":"10.1002\/cncr.25332","article-title":"Risk of mortality in patients with cancer who experience febrile neutropenia","volume":"116","author":"Lyman","year":"2010","journal-title":"Cancer"},{"key":"2026010713412918600_oyaf415-B7","doi-asserted-by":"crossref","first-page":"109","DOI":"10.6004\/jnccn.2008.0012","article-title":"Risk and timing of neutropenic events in adult cancer patients receiving chemotherapy: the results of a prospective nationwide study of oncology practice","volume":"6","author":"Crawford","year":"2008","journal-title":"J Natl Compr Canc Netw"},{"key":"2026010713412918600_oyaf415-B8","doi-asserted-by":"crossref","first-page":"P5-18-05","DOI":"10.1158\/0008-5472.SABCS11-P5-18-05","article-title":"P5-18-05: incidence of febrile neutropenia in patients treated with docetaxel and cyclophosphamide (TC) for adjuvant breast cancer","volume":"71","author":"Yee","year":"2011","journal-title":"Cancer Res"},{"key":"2026010713412918600_oyaf415-B9","doi-asserted-by":"crossref","first-page":"9061","DOI":"10.1200\/jco.2011.29.15_suppl.9061","article-title":"Incidence of febrile neutropenia with docetaxel plus cyclophosphamide in a university-based breast oncology clinic","volume":"29","author":"Soni","year":"2011","journal-title":"J Clin Oncol"},{"key":"2026010713412918600_oyaf415-B10","doi-asserted-by":"crossref","first-page":"e12073","DOI":"10.1200\/JCO.2017.35.15_suppl.e12073","article-title":"Incidence of febrile neutropenia with use of docetaxel plus cyclophosphamide (TC) for breast cancer","volume":"35","author":"Patel","year":"2017","journal-title":"J Clin Oncol"},{"key":"2026010713412918600_oyaf415-B11","doi-asserted-by":"crossref","first-page":"436","DOI":"10.6004\/jnccn.2022.0026","article-title":"Hematopoietic growth factors, version 1.2022: featured updates to the NCCN guidelines","volume":"20","author":"Griffiths","year":"2022","journal-title":"J Natl Compr Canc Netw"},{"key":"2026010713412918600_oyaf415-B12","doi-asserted-by":"crossref","first-page":"1903","DOI":"10.1093\/annonc\/mdy311","article-title":"Overall survival and risk of second malignancies with cancer chemotherapy and G-CSF support","volume":"29","author":"Lyman","year":"2018","journal-title":"Ann Oncol"},{"key":"2026010713412918600_oyaf415-B13","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1007\/s00508-023-02300-6","article-title":"Optimal use of granulocyte colony-stimulating factor prophylaxis to improve survival in cancer patients receiving treatment: an expert view","volume":"136","author":"Gascon","year":"2024","journal-title":"Wien Klin Wochenschr"},{"key":"2026010713412918600_oyaf415-B14","doi-asserted-by":"crossref","first-page":"12","DOI":"10.6004\/jnccn.2020.0002","article-title":"Hematopoietic growth factors, version 1.2020: featured updates to the NCCN guidelines","volume":"18","author":"Becker","year":"2020","journal-title":"J Natl Compr Canc Netw"},{"key":"2026010713412918600_oyaf415-B15","first-page":"2619","article-title":"The effectiveness and safety of same-day versus next-day administration of long-acting granulocyte colony-stimulating factors for the prophylaxis of chemotherapy-induced neutropenia: a systematic review","volume":"25","author":"Lyman","year":"2017","journal-title":"Support Care Cancer"},{"key":"2026010713412918600_oyaf415-B16","doi-asserted-by":"crossref","first-page":"4709","DOI":"10.1182\/blood-2018-99-114282","article-title":"Incidence of neutropenic fever at a safety net hospital in cancer chemotherapy patients receiving prophylactic pegfilgrastim manual injection compared to the on-body auto-injector","volume":"132","author":"Jindal","year":"2018","journal-title":"Blood"},{"key":"2026010713412918600_oyaf415-B17","first-page":"119","article-title":"Comparing grade 4 neutropenia associated with pegfilgrastim administered via the onpro device versus manual injection with a prefilled syringe","volume":"8","author":"Townley","year":"2018","journal-title":"J Hematol Oncol Pharm"},{"key":"2026010713412918600_oyaf415-B18","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1177\/0018578719867659","article-title":"Retrospective analysis of clinical outcomes associated with the use of pegfilgrastim on-body injector in patients receiving chemotherapy requiring granulocyte colony-stimulating factor support","volume":"56","author":"Patel","year":"2021","journal-title":"Hosp Pharm"},{"key":"2026010713412918600_oyaf415-B19","author":"Neulasta"},{"key":"2026010713412918600_oyaf415-B20","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1002\/acm2.13156","article-title":"Initial testing of pegfilgrastim (neulasta onpro) on-body injector in multiple radiological imaging environments","volume":"22","author":"Long","year":"2021","journal-title":"J Appl Clin Med Phys"},{"key":"2026010713412918600_oyaf415-B21","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/j.exphem.2020.09.199","article-title":"Eflapegrastim\u2019s enhancement of efficacy compared with pegfilgrastim in neutropenic rats supports potential for same-day dosing","volume":"92","author":"Barrett","year":"2020","journal-title":"Exp Hematol"},{"key":"2026010713412918600_oyaf415-B22","first-page":"241","article-title":"Evaluation of same-day versus next-day administration of pegfilgrastim in patients with breast cancer","volume":"13","author":"Weise","year":"2023","journal-title":"J Hematol Oncol Pharm"},{"key":"2026010713412918600_oyaf415-B23","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1007\/s10549-015-3590-1","article-title":"Myelodysplastic syndrome and acute myeloid leukemia following adjuvant chemotherapy with and without granulocyte colony-stimulating factors for breast cancer","volume":"154","author":"Calip","year":"2015","journal-title":"Breast Cancer Res Treat"},{"key":"2026010713412918600_oyaf415-B24","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1200\/JOP.091094","article-title":"Pegfilgrastim on the same day versus next day of chemotherapy in patients with breast cancer, non\u2013small-cell lung cancer, ovarian cancer, and non-Hodgkin\u2019s lymphoma: results of four multicenter, double-blind, randomized phase II studies","volume":"6","author":"Burris","year":"2010","journal-title":"J Oncol Pract"},{"key":"2026010713412918600_oyaf415-B25","first-page":"100466","article-title":"Use of prophylactic pegfilgrastim for chemotherapy-induced neutropenia in the US: a review of adherence to present guidelines for usage","volume":"29","author":"Crawford","year":"2021","journal-title":"Cancer Treat Res Commun"},{"key":"2026010713412918600_oyaf415-B26","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1007\/s40487-022-00207-2","article-title":"Pegfilgrastim biosimilars in US supportive oncology: a narrative review of administration options and economic considerations to maximize patient benefit","volume":"10","author":"Humphreys","year":"2022","journal-title":"Oncol Ther"},{"key":"2026010713412918600_oyaf415-B27","doi-asserted-by":"crossref","first-page":"796","DOI":"10.6004\/jadpro.2022.13.8.6","article-title":"Meta-analysis of same-day pegfilgrastim administration stratified by myelotoxic febrile neutropenia risk and tumor type","volume":"13","author":"Alrawashdh","year":"2022","journal-title":"J Adv Pract Oncol"},{"key":"2026010713412918600_oyaf415-B28","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/j.critrevonc.2017.11.005","article-title":"Impact of chemotherapy-induced neutropenia (CIN) and febrile neutropenia (FN) on cancer treatment outcomes: an overview about well-established and recently emerging clinical data","volume":"120","author":"Lalami","year":"2017","journal-title":"Crit Rev Oncol Hematol"},{"key":"2026010713412918600_oyaf415-B29","doi-asserted-by":"crossref","first-page":"2551","DOI":"10.2217\/fon-2022-0365","article-title":"Real-world febrile neutropenia rates with same-day versus next-day pegfilgrastim after myelosuppressive chemotherapy","volume":"18","author":"Kitchen","year":"2022","journal-title":"Future Oncol"}],"container-title":["The Oncologist"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/oncolo\/advance-article-pdf\/doi\/10.1093\/oncolo\/oyaf415\/65901005\/oyaf415.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/31\/1\/oyaf415\/65901005\/oyaf415.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/31\/1\/oyaf415\/65901005\/oyaf415.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,7]],"date-time":"2026-01-07T18:41:38Z","timestamp":1767811298000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/oncolo\/article\/doi\/10.1093\/oncolo\/oyaf415\/8380366"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,15]]},"references-count":29,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,12,27]]}},"URL":"https:\/\/doi.org\/10.1093\/oncolo\/oyaf415","relation":{},"ISSN":["1083-7159","1549-490X"],"issn-type":[{"value":"1083-7159","type":"print"},{"value":"1549-490X","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,1]]},"published":{"date-parts":[[2025,12,15]]},"article-number":"oyaf415"}}